Free Trial

Exagen (XGN) Insider Trading & Ownership

Exagen logo
$2.57
+0.14 (+5.76%)
(As of 11/1/2024 ET)

Exagen (NASDAQ:XGN) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
26.10%
Number Of
Insiders Buying
(Last 12 Months)
1
Amount Of
Insider Buying
(Last 12 Months)
$77,569.92
Number Of
Insiders Selling
(Last 12 Months)
1
Amount Of
Insider Selling
(Last 12 Months)
$24,417.44
Get XGN Insider Trade Alerts

Want to know when executives and insiders are buying or selling Exagen stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

XGN Insider Buying and Selling by Quarter

Exagen Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/16/2024John AballiCEOBuy40,401$1.92$77,569.92  
3/4/2024Kamal AdawiCFOSell12,784$1.91$24,417.44  
(Data available from 1/1/2013 forward)

XGN Insider Trading Activity - Frequently Asked Questions

The list of insiders at Exagen includes James L L Tullis, John Aballi, Kamal Adawi, and Mark Hazeltine. Learn more on insiders at XGN.

26.10% of Exagen stock is owned by insiders. Learn more on XGN's insider holdings.

The following insiders have purchased XGN shares in the last 24 months: James L L Tullis ($519.37), and John Aballi ($318,769.92).

Insiders have purchased a total of 130,568 XGN shares in the last 24 months for a total of $319,289.29 bought.

The following insiders have sold XGN shares in the last 24 months: John Aballi ($59,183.25), Kamal Adawi ($24,417.44), and Mark Hazeltine ($15,658.49).

Insiders have sold a total of 52,424 Exagen shares in the last 24 months for a total of $99,259.18 sold.

Exagen Key Executives

  • Dr. Tina S. Nova Ph.D. (Age 70)
    Executive Chairman of the Board of Directors
    Compensation: $65k
  • Mr. John Aballi (Age 39)
    CEO, President & Director
    Compensation: $558.84k
    1 recent trades
  • Mr. Kamal Adawi M.S. (Age 45)
    MBA, CFO & Corporate Secretary
    Compensation: $483.28k
  • Ryan Douglas
    Investors Relations Officer
  • Mr. John Wegener (Age 55)
    Senior Vice President of Sales and Marketing
  • Dr. Andrew L. Concoff FACR
    M.D., Chief Innovation Officer & Member of Rheumatoid Arthritis Scientific Advisory Board
  • Dr. Michael I. Nerenberg M.D. (Age 69)
    Chief Medical Officer


This page (NASDAQ:XGN) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners